Patient baseline characteristics
| Patients (N = 41) | |
|---|---|
| Median age (range), y | 54 (22–77) |
| Male/female (n) | 20/21 |
| ECOG performance statusa, n | |
| 0 | 21 |
| 1 | 19 |
| 2 | 0 |
| Primary tumor type, n (%) | |
| Melanoma | 6 (15) |
| Breast | 5 (12) |
| Kidney | 4 (10) |
| Ovarian | 4 (10) |
| Liposarcoma | 4 (10) |
| Colon | 3 (7) |
| Other | 15 (37) |
| Prior therapy, n (%) | |
| Any | 41 (100) |
| Chemotherapy | 34 (83) |
| 1–2 regimens | 21 (51) |
| 3 regimens | 12 (29) |
| >3 regimensb | 1 (2) |
| Hormonal | 4 (10) |
| Immunotherapy/biologic | 7 (17) |
| Radiotherapy | 17 (42) |
| Surgery | 37 (90) |
↵aECOG PS score not available for one patient.
↵bOne patient who had received more than 3 prior cytotoxic chemotherapy regimens was enrolled into the study. Although the relevant inclusion criterion was such that patients were eligible with up to 3 prior cytotoxic chemotherapy regimens, this patient was enrolled with the agreement of the study sponsor and does not, therefore, represent a protocol deviation. The inclusion of this patient in the analysis populations did not affect the conduct or conclusions of the study.